◆英語タイトル:Immuron Ltd (IMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013609
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Immuron Ltd (Immuron), formerly Anadis Limited is a biopharmaceutical company that conducts research and develops polyclonal antibody products for humans. The company develops and produces an orally stable therapeutic for various immune mediated and inflammatory disorders. Immuron’s products include Travelan, IMM 124-E and IMM 529. It produces therapeutics for non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders. The company’s product Travelan is a natural product designed to prevent infection by Enterotoxigenic Escherichia coli. Immuron is headquartered in Melbourne, Victoria, Australia.
Immuron Ltd (IMC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immuron Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immuron Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immuron Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Immuron Expands R&D Agreement with Walter Reed Army Institute 10
Immuron Enters into Agreement with One Way Liver Genomics 11
Immuron Enters Into Co-Development Agreement With Monash University 12
Licensing Agreements 13
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 13
Equity Offering 14
Immuron Prices Public Offering of American Depositary Shares and Warrants for USD6 Million 14
Immuron Raises USD4 Million in Rights Offering of Shares 16
Immuron Raises USD0.1 Million in Private Placement of Shares 17
Immuron Completes Rights Offering Of Shares For US$1.6 Million 18
Immuron Completes Private Placement Of Shares For US$0.06 Million 19
Immuron Completes Rights Offering Of Shares For US$0.29 Million 20
Immuron Completes Private Placement Of Shares For US$0.5 Million 21
Immuron Announces Rights Issue Of Common Shares For US$4.6 Million 22
Debt Offering 23
Immuron Raises USD1.2 Million in Private Placement of Notes 23
Immuron Ltd – Key Competitors 24
Immuron Ltd – Key Employees 25
Immuron Ltd – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 08, 2017: Travelan Experiences Strong Q1 FY2018 Sales Growth 27
Corporate Communications 28
Aug 03, 2017: Immuron Announces Management Changes 28
Product News 29
08/18/2016: US NIH Grants Funding for Second Fatty Liver Trial; Pediatric NASH Study with Emory University 29
May 25, 2016: NASH Phase II Trial Reaches 50% Patient Recruitment Milestone 30
01/19/2017: Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University 31
Clinical Trials 32
Feb 20, 2017: Immuron Completes Phase II NASH Clinical Trial Recruitment 32
Oct 10, 2016: NASH Phase II Trial Reaches 90 (75%) Patient Recruitment Milestone 33
May 25, 2016: NASH Phase II Trial Reaches 50% Patient Recruitment Milestone 34
Other Significant Developments 35
Jun 29, 2016: Immuron Significantly Expands US Distribution Reach with McKesson Agreement 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Immuron Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immuron Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immuron Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Immuron Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immuron Expands R&D Agreement with Walter Reed Army Institute 10
Immuron Enters into Agreement with One Way Liver Genomics 11
Immuron Enters Into Co-Development Agreement With Monash University 12
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 13
Immuron Prices Public Offering of American Depositary Shares and Warrants for USD6 Million 14
Immuron Raises USD4 Million in Rights Offering of Shares 16
Immuron Raises USD0.1 Million in Private Placement of Shares 17
Immuron Completes Rights Offering Of Shares For US$1.6 Million 18
Immuron Completes Private Placement Of Shares For US$0.06 Million 19
Immuron Completes Rights Offering Of Shares For US$0.29 Million 20
Immuron Completes Private Placement Of Shares For US$0.5 Million 21
Immuron Announces Rights Issue Of Common Shares For US$4.6 Million 22
Immuron Raises USD1.2 Million in Private Placement of Notes 23
Immuron Ltd, Key Competitors 24
Immuron Ltd, Key Employees 25
Immuron Ltd, Other Locations 26
Immuron Ltd, Subsidiaries 26